Press "Enter" to skip to content

Lupin partners with AbbVie to develop, commercialise novel oncology drug

Under the terms of the agreement, AbbVie will pay Lupin an upfront payment of USD 30 million (approx Rs 210 crore) for an exclusive licence to the programme.

Original source:

Also Read:   USFDA finds significant violations of CGMP at Cadila's Moraiya plant